Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.19% | -25.96% | -24.46% | -25.19% | -11.93% |
| Total Depreciation and Amortization | 8.98% | 100.20% | 71.95% | 44.62% | 17.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.11% | -117.40% | -81.14% | -57.70% | -53.88% |
| Change in Net Operating Assets | 314.16% | 4,488.49% | 223.90% | 360.68% | 187.92% |
| Cash from Operations | -24.16% | -26.39% | -8.54% | -3.49% | -12.37% |
| Capital Expenditure | 32.98% | 29.47% | 27.43% | 67.12% | 32.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 471.07% | 134.27% | 70.71% | 44.29% | -540.29% |
| Cash from Investing | 462.21% | 130.54% | 69.60% | 45.15% | -618.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 79.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 113.34% | -- | -- | -- | 77.09% |
| Foreign Exchange rate Adjustments | -74.30% | 194.16% | -354.10% | -85.47% | -167.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.72% | -22.78% | -7.02% | -3.45% | -6.93% |